Hereditary Angioedema (HAE) Market - Future Scope Detailed Analysis to 2024

Global Hereditary Angioedema (HAE) Market: Overview

Hereditary angioedema (HAE) is a rare inherited disease, which leads to repeated episodes of swelling beneath the surface of the skin. Hereditary angioedema is confined to the face, tongue, feet, legs, hands and arms. However, it sometimes leads to swelling in airways such as trachea, larynx or intestinal tract may prove out to be fatal.

View Report @ http://www.transparencymarketresearch.com/hereditary-angioedema-market.html

For the treatment of hereditary angioedema, currently there are no medications available; hence, the medicines that are prescribed to patients help in management of the disease symptoms. On the basis of the treatment of hereditary angioedema, the market is segmented into different classes of drugs which are used to manage the symptoms of disease which are as follows:

C1-inhibitors (Cinryze, Berinert, ruconest)
Ecallantide (Kalbitor)
Icatibant (Firazyr)
C1-inhibitors are considered as the best treatment method for hereditary angioedema, and berinert among them captures the major share of market. This class of the drugs helps in managing the acute attacks of HAE. Among all the drugs, Berinert was the first and only therapy that received approval in Europe in 2008. However, in between 2008 and 2011, three drugs got approval in Europe which include cinryze, firazyr and ruconest while four drugs were approved by Food and Drug Association (FDA) in the U.S. which included berinert, cinryze, firazyr and kalbitor. In addition to this, prophylactic treatment is also recommended by the doctors for preventing the hereditary angioedema attacks. For prophylactic treatment, cinryze and danazol are the two drugs which are approved by the FDA. In spite of their high cost, these drugs are growing at faster pace and are expected to boost the hereditary angioedema market in forecast period. 

Get accurate market forecast and analysis on the Market. Request a sample to stay abreast on the key trends impacting this market.

http://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=17135

Global Hereditary Angioedema (HAE) Market: Key Segments

Hereditary angioedema market can be segmented on the basis of the types of hereditary angioedema, diagnosis methods and treatment methods. On the basis of types of HAE, hereditary angioedema market is classified into three types namely:

Type I HAE
Type II HAE
Type III HAE
Type I HAE captures the major share of the hereditary angioedema market followed by type II HAE. Type I and Type II HAE occurs due to mutation in SERPING1 gene. This gene is responsible for making C1 protein, small protein that assists human immune system. However, type III HAE is associated with Factor XII gene which assists the blood clotting process. Type III HAE is the hereditary angioedema affecting primarily women, and it becomes worse in case of pregnancy and use of birth control pills. On the basis of the diagnosis method the hereditary angioedema market is differentiated into two types which include:

Blood tests
Abdominal radiography
Chest radiography
Abdominal ultrasonography
Blood tests capture the major share of the hereditary angioedema diagnosis market. The factors which are analyzed for confirmation of disease include C1 esterase inhibitor level, C4 and C2 levels and C1q levels in the blood sample. Abdominal radiography or abdominal ultrasonography is performed during the attacks of gastrointestinal edema while chest radiography is performed to confirm pleural effusions.  

Global Hereditary Angioedema (HAE) Market: Trends 

Extensive research and development associated with the treatment methods for HAE is the major factor which is driving the hereditary angioedema market. As for instance, one of the major market players BioCryst Pharmaceuticals, Inc. has successfully completed the phase II clinical trials of BCX 4161 and it is expected that this drug will provide efficient results in the forecast period resulting in the growth of the market. However, high cost associated with the available treatments and less awareness about the disease condition are the two major factors which are restraining the hereditary angioedema market. Geographically, HAE market is classified into four segments which include North America, Europe, Asia-Pacific and Rest of the World.

Global Hereditary Angioedema (HAE) Market: Companies Mentioned in the report

Other major market players of hereditary angioedema market include Isis Pharmaceuticals, Inc., Pharming Group N.V., Dyax Corporation, ViroPharma, Inc., CSL Limited and iBio, Inc. 

 

About Us

Transparency Market Research (TMR) is a global market intelligence company providing business information reports and services. The company’s exclusive blend of quantitative forecasting and trend analysis provides forward-looking insight for thousands of decision makers. TMR’s experienced team of analysts, researchers, and consultants use proprietary data sources and various tools and techniques to gather and analyze information.

Contact us:

Transparency Market Research

90 State Street,

Suite 700,

Albany

NY – 12207

United States

Tel: +1-518-618-1030

USA – Canada Toll Free 866-552-3453

Email: sales@transparencymarketresearch.com

Website: http://www.transparencymarketres.com

This release was published on openPR.